ArticleScientific reports2016
IL-34 is associated with the presence and severity of renal dysfunction and coronary artery disease in patients with heart failure.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 39 citations in OpenAlex.
- IL-34 aggravates myocardial ischemia-reperfusion injury by upregulating the HMGB1-IL-17A-IL-6 axis through the JAK signaling pathway.PloS one · 2025Article
- Cut-off value for interleukin-34 as an additional potential inflammatory biomarker for estimation of slow coronary flow risk.BMC cardiovascular disorders · 2024Observational
- Combination of IL-34 and AFP improves the diagnostic value during the development of HBV related hepatocellular carcinoma.Clinical and experimental medicine · 2023Article
- Bioinformatics and Experimental Analyses Reveal Immune-Related LncRNA-mRNA PairInternational journal of molecular sciences · 2022Article
- Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone-Translational Aspects and Clinical Perspectives across Multiple Organ Systems.International journal of molecular sciences · 2022Review
- Prognostic value of interleukin-34 and interleukin-38 in patients with newly diagnosed atrial fibrillation.Frontiers in cardiovascular medicine · 2022Article
- IL-34 and coronary heart disease complicated with diabetes mellitus.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2021Article
- Reno-protective effect of IL-34 inhibition on cisplatin-induced nephrotoxicity in mice.PloS one · 2021Article
- Clinical Implications of IL-32, IL-34 and IL-37 in Atherosclerosis: Speculative Role in Cardiovascular Manifestations of COVID-19.Frontiers in cardiovascular medicine · 2021Review
- Emerging roles of IL-34 in health and disease.The Journal of experimental medicine · 2020Review
- Immunomodulation of Interleukin-34 and its Potential Significance as a Disease Biomarker and Therapeutic Target.International journal of biological sciences · 2019Review
- IL-34 and CSF-1 display an equivalent macrophage differentiation ability but a different polarization potential.Scientific reports · 2018Article
- Increased Serum Interleukin-34 Levels Are Related to the Presence and Severity of Cardiac Dysfunction in Patients With Ischemic Cardiomyopathy.Frontiers in physiology · 2018Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pro-inflammatory mediators are identified in patients with heart failure (HF), some of which may be used as biomarkers with diagnostic or prognostic value. As an additional ligand of Colony Stimulating Factor-1 Receptor (CSF-1R), interleukin-34 (IL-34) has been identified as a pro-inflammatory cytokine participating in chronic heart failure (CHF). However, the potential impact of IL-34 in CHF complications remains unknown. In order to determine the clinical significance of serum IL-34 in CHF patients, especially those with kidney dysfunction and coronary artery disease (CAD) comorbid conditions, serum IL-34 was measured in 510 consecutive patients with CHF in a cross-sectional study. The present study demonstrated that higher serum IL-34 levels were associated with poorer renal function and more severe anemia in patients with CHF. After adjusting for age, gender, conventional risk factors, and other significant covariates, IL-34 positively correlated with the presence and severity of renal dysfunction (as measured by eGFR and cystatin C) on multivariable linear and logistic regression analysis. IL-34 was also demonstrated to be an independent risk factor for CAD among HF patients. In conclusion, elevated serum IL-34 levels were demonstrated to be independently associated with renal insufficiency and CAD in patients with CHF, regardless of the systolic function.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.